Janney Montgomery Scott LLC Lowers Stock Holdings in Krystal Biotech, Inc. $KRYS

Janney Montgomery Scott LLC trimmed its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 94.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,340 shares of the company's stock after selling 43,595 shares during the period. Janney Montgomery Scott LLC's holdings in Krystal Biotech were worth $322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in KRYS. Brooklyn Investment Group boosted its position in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after buying an additional 105 shares during the period. Twin Tree Management LP bought a new stake in shares of Krystal Biotech in the 1st quarter valued at about $29,000. Fifth Third Bancorp raised its holdings in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after purchasing an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Krystal Biotech in the 1st quarter valued at about $74,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Weiss Ratings restated a "hold (c)" rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the stock a "buy" rating in a research report on Friday. Chardan Capital cut their price objective on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research report on Friday, August 22nd. Finally, Citigroup reaffirmed a "neutral" rating and issued a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $223.00.

Krystal Biotech Trading Up 1.0%

NASDAQ:KRYS opened at $190.23 on Monday. The company has a market cap of $5.51 billion, a PE ratio of 38.66 and a beta of 0.64. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84. The company's 50 day moving average is $160.70 and its two-hundred day moving average is $151.10.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.